BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wu L, Wen Z, Song Y, Wang L. A novel autophagy-related lncRNA survival model for lung adenocarcinoma. J Cell Mol Med 2021;25:5681-90. [PMID: 33987935 DOI: 10.1111/jcmm.16582] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 25.0] [Reference Citation Analysis]
Number Citing Articles
1 Chen X, Wu J, Wang J. Pyroptosis: A new insight of non-small-cell lung cancer treatment. Front Oncol 2022;12. [DOI: 10.3389/fonc.2022.1013544] [Reference Citation Analysis]
2 Feng C, Che W, Liang H, Zhang H, Lan C, Wu B, Lin W, Chen Y, Xu Y. Mining Database to Identify Aging-Related Molecular Subtype and Prognostic Signature in Lung Adenocarcinoma. Journal of Oncology 2022;2022:1-16. [DOI: 10.1155/2022/9142903] [Reference Citation Analysis]
3 Chen H, Xu S, Hu Z, Wei Y, Zhu Y, Fang S, Pan Q, Liu K, Li N, Zhu L, Xu G. Bioinformatics algorithm for lung adenocarcinoma based on macropinocytosis-related long noncoding RNAs as a reliable indicator for predicting survival outcomes and selecting suitable anti-tumor drugs. Medicine 2022;101:e30543. [DOI: 10.1097/md.0000000000030543] [Reference Citation Analysis]
4 Liu Y, Yu M, Cheng X, Zhang X, Luo Q, Liao S, Chen Z, Zheng J, Long K, Wu X, Qu W, Gong M, Song Y. A novel LUAD prognosis prediction model based on immune checkpoint-related lncRNAs. Front Genet 2022;13:1016449. [DOI: 10.3389/fgene.2022.1016449] [Reference Citation Analysis]
5 Tong F, Xu L, Xu S, Zhang M. Identification of an autophagy-related 12-lncRNA signature and evaluation of NFYC-AS1 as a pro-cancer factor in lung adenocarcinoma. Front Genet 2022;13:834935. [DOI: 10.3389/fgene.2022.834935] [Reference Citation Analysis]
6 Peña-flores JA, Bermúdez M, Ramos-payán R, Villegas-mercado CE, Soto-barreras U, Muela-campos D, Álvarez-ramírez A, Pérez-aguirre B, Larrinua-pacheco AD, López-camarillo C, López-gutiérrez JA, Garnica-palazuelos J, Estrada-macías ME, Cota-quintero JL, Barraza-gómez AA. Emerging role of lncRNAs in drug resistance mechanisms in head and neck squamous cell carcinoma. Front Oncol 2022;12:965628. [DOI: 10.3389/fonc.2022.965628] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Liu J, Liu Q, Shen H, Liu Y, Wang Y, Wang G, Du J. Identification and Validation of a Three Pyroptosis-Related lncRNA Signature for Prognosis Prediction in Lung Adenocarcinoma. Front Genet 2022;13:838624. [DOI: 10.3389/fgene.2022.838624] [Reference Citation Analysis]
8 Zheng Y, Xu J, Lin J, Lin Y, Chen G. A Novel Necroptosis-Related lncRNA Signature for Osteosarcoma. Computational and Mathematical Methods in Medicine 2022;2022:1-9. [DOI: 10.1155/2022/8003525] [Reference Citation Analysis]
9 Chen H, Xie Z, Li Q, Qu G, Tan N, Zhang Y. Risk coefficient model of necroptosis-related lncRNA in predicting the prognosis of patients with lung adenocarcinoma. Sci Rep 2022;12:11005. [PMID: 35768485 DOI: 10.1038/s41598-022-15189-4] [Reference Citation Analysis]
10 Yang Y, Shi L, Zhang J, Zheng Y, Wu G, Sun J, Liu M, Chen Z, Wang Y, Ji R, Guo Q, Zhou Y. A Novel Matrisomal-Related LncRNA Signature Associated With Survival Outcome and Immune Evasion in Patients With Gastric Cancer. Front Oncol 2022;12:926404. [DOI: 10.3389/fonc.2022.926404] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang P, Chen L, Wu S, Ye B, Chen C, Shi L. Construction of a Metabolism-Related Long Non-Coding RNAs-Based Risk Score Model of Hepatocellular Carcinoma for Prognosis and Personalized Treatment Prediction. Pathol Oncol Res 2022;28:1610066. [PMID: 35685867 DOI: 10.3389/pore.2022.1610066] [Reference Citation Analysis]
12 Zhao R, Ding D, Ding Y, Han R, Wang X, Zhu C. Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes. Front Genet 2022;13:828543. [DOI: 10.3389/fgene.2022.828543] [Reference Citation Analysis]
13 Chen H, Zhou C, Hu Z, Sang M, Ni S, Wu J, Pan Q, Tong J, Liu K, Li N, Zhu L, Xu G. Construction of an algorithm based on oncosis-related LncRNAs comprising the molecular subtypes and a risk assessment model in lung adenocarcinoma. J Clin Lab Anal 2022;:e24461. [PMID: 35476781 DOI: 10.1002/jcla.24461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Liu X, Wang Z, Wang L, Wang Y, Wang Y, Yang S, Zhang Y. Signature involved in immune-related lncRNA pairs for predicting the immune landscape of cervical cancer. Int J Biol Markers. [DOI: 10.1177/03936155221091832] [Reference Citation Analysis]
15 Enguita FJ, Lúcia Leitão A, Mcdonald JT, Zaksas V, Das S, Galeano D, Taylor D, Wurtele ES, Saravia-butler A, Baylin SB, Meller R, Porterfield DM, Wallace DC, Schisler JC, Mason CE, Beheshti A. The interplay between lncRNAs, RNA-binding proteins and viral genome during SARS-CoV-2 infection reveals strong connections with regulatory events involved in RNA metabolism and immune response.. [DOI: 10.1101/2022.03.26.485903] [Reference Citation Analysis]
16 Li Y, Sun X. An Effective Hypoxia-Related Long Non-Coding RNA Assessment Model for Prognosis of Lung Adenocarcinoma. Front Genet 2022;13:768971. [DOI: 10.3389/fgene.2022.768971] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Zhu J, Guan J, Ji X, Song Y, Xu X, Wang Q, Zhang Q, Guo R, Wang R, Zhang R. A two-phase comprehensive NSCLC prognostic study identifies lncRNAs with significant main effect and interaction. Mol Genet Genomics 2022. [PMID: 35218396 DOI: 10.1007/s00438-022-01869-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Gao C, Kong N, Zhang F, Tang T, Li J, Ding H, Sun Z, Wu L, Xu M. Risk stratification of lung adenocarcinoma using a nomogram combined with ferroptosis-related LncRNAs and subgroup analysis with immune and N6-methyladenosine modification. BMC Med Genomics 2022;15. [DOI: 10.1186/s12920-022-01164-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Chen H, Hu Z, Sang M, Ni S, Lin Y, Wu C, Mu Y, Liu K, Wu S, Li N, Xu G. Identification of an Autophagy-Related lncRNA Prognostic Signature and Related Tumor Immunity Research in Lung Adenocarcinoma. Front Genet 2021;12:767694. [PMID: 34956321 DOI: 10.3389/fgene.2021.767694] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
20 Lu S, Shan N, Chen X, Peng F, Wang Y, Long H. A novel immune-related long non-coding RNAs risk model for prognosis assessment of lung adenocarcinoma. Aging (Albany NY) 2021;13:25550-63. [PMID: 34905504 DOI: 10.18632/aging.203772] [Reference Citation Analysis]
21 Weng C, Wang L, Liu G, Guan M, Lu L. Identification of a N6-Methyladenosine (m6A)-Related lncRNA Signature for Predicting the Prognosis and Immune Landscape of Lung Squamous Cell Carcinoma. Front Oncol 2021;11:763027. [PMID: 34868980 DOI: 10.3389/fonc.2021.763027] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
22 Izadi M, Ali TA, Pourkarimi E. Over Fifty Years of Life, Death, and Cannibalism: A Historical Recollection of Apoptosis and Autophagy. Int J Mol Sci 2021;22:12466. [PMID: 34830349 DOI: 10.3390/ijms222212466] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
23 Ma YS, Hou LK, Yao SH, Liu JB, Yu XC, Shi Y, Yang XL, Wu W, Wu CY, Jiang GX, Fu D. Elevated Stratifin promotes cisplatin-based chemotherapy failure and poor prognosis in non-small cell lung cancer. Mol Ther Oncolytics 2021;22:326-35. [PMID: 34553022 DOI: 10.1016/j.omto.2021.07.005] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
24 Zhou W, Bai C, Long C, Hu L, Zheng Y. Construction and Characterization of Long Non-Coding RNA-Associated Networks to Reveal Potential Prognostic Biomarkers in Human Lung Adenocarcinoma. Front Oncol 2021;11:720400. [PMID: 34513699 DOI: 10.3389/fonc.2021.720400] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
25 Zhang J, Ding R, Wu T, Jia J, Cheng X. Autophagy-Related Genes and Long Noncoding RNAs Signatures as Predictive Biomarkers for Osteosarcoma Survival. Front Cell Dev Biol 2021;9:705291. [PMID: 34513835 DOI: 10.3389/fcell.2021.705291] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
26 Song J, Sun Y, Cao H, Liu Z, Xi L, Dong C, Yang R, Shi Y. A novel pyroptosis-related lncRNA signature for prognostic prediction in patients with lung adenocarcinoma. Bioengineered 2021;12:5932-49. [PMID: 34488540 DOI: 10.1080/21655979.2021.1972078] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 26.0] [Reference Citation Analysis]
27 Shao J, Zhang B, Kuai L, Li Q. Integrated analysis of hypoxia-associated lncRNA signature to predict prognosis and immune microenvironment of lung adenocarcinoma patients. Bioengineered 2021;12:6186-200. [PMID: 34486476 DOI: 10.1080/21655979.2021.1973874] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 12.0] [Reference Citation Analysis]
28 Wu L, Wen Z, Song Y, Wang L. A novel autophagy-related lncRNA survival model for lung adenocarcinoma. J Cell Mol Med 2021;25:5681-90. [PMID: 33987935 DOI: 10.1111/jcmm.16582] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 25.0] [Reference Citation Analysis]
29 Miao Z, Liu L, Wang D, Jiang C, Zhu C, Zheng H, Zhang L. Three Novel Autophagy-Related lncRNAs as Prognostic Biomarkers for Lung Adenocarcinoma. ALC 2021;10:65-77. [DOI: 10.4236/alc.2021.104007] [Reference Citation Analysis]